A Phase 3 interventional study of Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution and Concurrent brimonidine 0.2% and 0.5% timolol in Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-04-03.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing brimonidine in Glaucoma — 1 open to participants now, 1 under way, none of them phase 3. brimonidine · Glaucoma.
Among the 23 studies testing brimonidine in Glaucoma, this one has the largest enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2005, is one of 3 in phase 3, and was the 9th registered.
1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.
Browse Glaucoma studies →1 of the 23 studies testing brimonidine in Glaucoma is open now, in 1 country. Recruiting first, the newest first:
Tulane University · Sites in United States
Ages 18+
By country, each count listing its studies:
brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 604 is above the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 56 across the 21 interventional studies. Of the 18 that completed or were terminated, 6 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
34 studies in Glaucoma by AbbVie: none open now, none under way, none of them phase 3. Of 33 finished, 23 (70%) have results posted.
Among the 34 studies in Glaucoma by AbbVie, this one is the 2nd largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2005, is one of 13 in phase 3, and was the 6th registered.
AbbVie’s Glaucoma studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing brimonidine in Glaucoma, from their registry updates:
Among AbbVie’s 34 in Glaucoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the safety of brimonidine/timolol fixed combination in glaucoma or ocular hypertension patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution
Drug: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution
Concurrent Brimonidine 0.2% and 0.5% Timolol
Drug: Concurrent brimonidine 0.2% and 0.5% timolol
Drug page: Brimonidine
Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)
Also known as: COMBIGAN™
Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)
Adverse Events
Time frame: Day 10
The record gives a start of Nov 2005, a primary completion of Jan 2007 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine